Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: MSRB2

Gene summary for MSRB2

Gene summary.

Gene information	Species	Human
	Gene symbol	MSRB2
	Gene ID	22921
	Gene name	methionine sulfoxide reductase B2
	Gene Alias	CBS-1
	Cytomap	10p12.2
	Gene Type	protein-coding
	GO ID	GO:0006807
	UniProtAcc	Q9Y3D2

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
22921	MSRB2	GSM4909281	Human	Breast	IDC	5.46e-06	3.55e-01	0.21
22921	MSRB2	GSM4909285	Human	Breast	IDC	1.52e-11	4.40e-01	0.21
22921	MSRB2	GSM4909289	Human	Breast	IDC	3.18e-04	5.20e-01	0.1064
22921	MSRB2	GSM4909293	Human	Breast	IDC	2.85e-12	4.19e-01	0.1581
22921	MSRB2	GSM4909294	Human	Breast	IDC	6.72e-03	3.28e-01	0.2022
22921	MSRB2	GSM4909296	Human	Breast	IDC	9.00e-04	2.68e-01	0.1524
22921	MSRB2	GSM4909301	Human	Breast	IDC	4.76e-11	4.72e-01	0.1577
22921	MSRB2	GSM4909304	Human	Breast	IDC	4.19e-07	4.29e-01	0.1636
22921	MSRB2	GSM4909306	Human	Breast	IDC	1.17e-02	3.49e-01	0.1564
22921	MSRB2	GSM4909308	Human	Breast	IDC	1.29e-07	2.86e-01	0.158
22921	MSRB2	GSM4909311	Human	Breast	IDC	8.76e-13	-6.77e-02	0.1534
22921	MSRB2	GSM4909315	Human	Breast	IDC	1.07e-17	7.08e-01	0.21
22921	MSRB2	GSM4909316	Human	Breast	IDC	1.92e-09	6.47e-01	0.21
22921	MSRB2	GSM4909319	Human	Breast	IDC	9.80e-21	9.84e-02	0.1563
22921	MSRB2	GSM4909321	Human	Breast	IDC	1.01e-02	7.41e-02	0.1559
22921	MSRB2	M1	Human	Breast	IDC	5.43e-04	2.84e-01	0.1577
22921	MSRB2	DCIS2	Human	Breast	DCIS	1.33e-51	2.29e-01	0.0085
22921	MSRB2	HTA11_1938_2000001011	Human	Colorectum	AD	1.25e-03	2.90e-01	-0.0811
22921	MSRB2	HTA11_347_2000001011	Human	Colorectum	AD	2.48e-08	2.68e-01	-0.1954
22921	MSRB2	HTA11_3361_2000001011	Human	Colorectum	AD	4.78e-03	2.48e-01	-0.1207

Page: 1 2 3 4 5 6 7 8

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Breast		IDC: Invasive ductal carcinoma
		DCIS: Ductal carcinoma in situ
		Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:0030041110	Esophagus	ESCC	actin filament polymerization	114/8552	191/18723	6.46e-05	4.92e-04	114
GO:000697912	Liver	Cirrhotic	response to oxidative stress	196/4634	446/18723	2.80e-19	5.86e-17	196
GO:000701512	Liver	Cirrhotic	actin filament organization	171/4634	442/18723	3.93e-11	2.30e-09	171
GO:005125812	Liver	Cirrhotic	protein polymerization	116/4634	297/18723	2.87e-08	9.78e-07	116
GO:000815412	Liver	Cirrhotic	actin polymerization or depolymerization	86/4634	218/18723	1.04e-06	2.13e-05	86
GO:003004112	Liver	Cirrhotic	actin filament polymerization	77/4634	191/18723	1.41e-06	2.79e-05	77
GO:000697922	Liver	HCC	response to oxidative stress	281/7958	446/18723	9.75e-19	1.24e-16	281
GO:005125822	Liver	HCC	protein polymerization	182/7958	297/18723	4.17e-11	1.58e-09	182
GO:000701522	Liver	HCC	actin filament organization	252/7958	442/18723	3.83e-10	1.25e-08	252
GO:000815422	Liver	HCC	actin polymerization or depolymerization	130/7958	218/18723	2.31e-07	4.14e-06	130
GO:003004122	Liver	HCC	actin filament polymerization	116/7958	191/18723	2.66e-07	4.68e-06	116
GO:000697920	Oral cavity	OSCC	response to oxidative stress	273/7305	446/18723	8.35e-22	1.65e-19	273
GO:005125820	Oral cavity	OSCC	protein polymerization	169/7305	297/18723	2.57e-10	7.17e-09	169
GO:000701520	Oral cavity	OSCC	actin filament organization	230/7305	442/18723	1.37e-08	2.77e-07	230
GO:000815418	Oral cavity	OSCC	actin polymerization or depolymerization	117/7305	218/18723	7.38e-06	8.04e-05	117
GO:003004118	Oral cavity	OSCC	actin filament polymerization	103/7305	191/18723	1.94e-05	1.87e-04	103
GO:0006979110	Oral cavity	LP	response to oxidative stress	181/4623	446/18723	5.74e-14	6.10e-12	181
GO:0051258110	Oral cavity	LP	protein polymerization	113/4623	297/18723	1.90e-07	5.92e-06	113
GO:0007015110	Oral cavity	LP	actin filament organization	143/4623	442/18723	1.44e-04	1.65e-03	143
GO:003004119	Oral cavity	LP	actin filament polymerization	69/4623	191/18723	2.65e-04	2.75e-03	69

Page: 1 2 3 4

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

MSRB2

deletion

Frame_Shift_Del

novel

c.350delA

p.His117LeufsTer14

p.H117Lfs*14

Q9Y3D2

protein_coding

TCGA-EW-A2FV-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

docetaxel

MSRB2

SNV

Missense_Mutation

c.168N>T

p.Lys56Asn

p.K56N

Q9Y3D2

protein_coding

deleterious(0.03)

possibly_damaging(0.573)

TCGA-AG-A002-01

Colorectum

rectum adenocarcinoma

Male

<65

I/II

Unknown

MSRB2

SNV

Missense_Mutation

novel

c.400N>A

p.Asp134Asn

p.D134N

Q9Y3D2

protein_coding

deleterious(0.01)

probably_damaging(1)

TCGA-A5-A0G1-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

I/II

Unknown

MSRB2

SNV

Missense_Mutation

novel

c.280N>A

p.Asp94Asn

p.D94N

Q9Y3D2

protein_coding

tolerated(0.36)

benign(0.423)

TCGA-AP-A0LM-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Chemotherapy

cisplatin

MSRB2

SNV

Missense_Mutation

c.122N>A

p.Ser41Tyr

p.S41Y

Q9Y3D2

protein_coding

deleterious(0.03)

benign(0.088)

TCGA-AX-A05Z-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Chemotherapy

adriamycin

MSRB2

SNV

Missense_Mutation

c.168N>T

p.Lys56Asn

p.K56N

Q9Y3D2

protein_coding

deleterious(0.03)

possibly_damaging(0.573)

TCGA-B5-A0JY-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Chemotherapy

doxorubicin

MSRB2

SNV

Missense_Mutation

c.168N>T

p.Lys56Asn

p.K56N

Q9Y3D2

protein_coding

deleterious(0.03)

possibly_damaging(0.573)

TCGA-D1-A17Q-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

MSRB2

SNV

Missense_Mutation

novel

c.274T>C

p.Cys92Arg

p.C92R

Q9Y3D2

protein_coding

deleterious(0)

probably_damaging(0.959)

TCGA-DI-A1BU-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Chemotherapy

paclitaxel

MSRB2

SNV

Missense_Mutation

novel

c.335C>T

p.Ser112Leu

p.S112L

Q9Y3D2

protein_coding

deleterious(0.01)

probably_damaging(0.969)

TCGA-EO-A22R-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

MSRB2

SNV

Missense_Mutation

c.122N>A

p.Ser41Tyr

p.S41Y

Q9Y3D2

protein_coding

deleterious(0.03)

benign(0.088)

TCGA-EO-A22U-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

I/II

Unknown

Page: 1 2 3

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1